We investigated the role of the PD-L1 expression, high microsatellite instability (MSI-H)/mismatch repair deficiency (dMMR), and tumor mutation burden (TMB) as predictive biomarkers of PD-1/PD-L1 inhibitors. The gene discussed is CD274; the disease is neoplasm.